|
TR201908591A2
|
|
A PHARMACEUTICAL COMPOSITION CONTAINING NAPROXEN AND SUMATRIPT
|
|
TR201820708A2
|
|
PHARMACEUTICAL COMPOSITION CONTAINING IBUPROPHEN, Pseudoephedrine and Ascorbic Acid
|
|
TR201820715A2
|
|
PHARMACEUTICAL COMPOSITION AND MANUFACTURING METHOD INCLUDING POSACONAZOL
|
|
TR201820589A2
|
|
STABLE PHARMACEUTICAL COMPOSITION CONTAINING PHESOTHERODINE
|
|
TR201820616A2
|
|
A PHARMACEUTICAL COMPOSITION CONTAINING IBUPROPHEN, Pseudoephedrine, ASKORBIC ACID and PROPOLIS
|
|
TR201820274A2
|
|
A PHARMACEUTICAL COMPOSITION CONTAINING IBUPROPHEN, Pseudoephedrine, and Ascorbic Acid
|
|
TR201819752A2
|
|
SOLID PHARMACEUTICAL COMPOSITION CONTAINING PINAVERIUM AND MEDAZEPAM
|
|
EP3116487A1
|
|
Pharmaceutical composition of cinacalcet
|
|
TR201309048A2
|
|
A dermal matrix and production method thereof having synergistic effects comprising microparticles which provides tissue repair
|
|
EP2778167A1
|
|
Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
|
|
WO2012153181A1
|
|
Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
|
|
WO2012095726A1
|
|
Pharmaceutical combination containing glucosamine salts and paracetamol for the treatment of osteoarthritis
|
|
WO2013098576A1
|
|
Immediate release pharmaceutical composition of valsartan
|
|
WO2013098577A1
|
|
Pharmaceutical compositions of bosentan
|
|
WO2013098578A1
|
|
Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
|
|
EP2425859A1
|
|
Olmesartan formulations
|
|
EP2389927A1
|
|
Pharmaceutical formulations of rasagiline
|
|
EP2389929A1
|
|
Pharmaceutical formulations of tenofovir
|
|
EP2394641A1
|
|
Pharmaceutical formulations of lornoxicam
|
|
EP2377521A1
|
|
Pharmaceutical formulations of telmisartan and diuretic combination
|
